The estimated Net Worth of Richard Hague is at least $1.22 Milhão dollars as of 9 August 2021. Mr Hague owns over 10,208 units of PolarityTE Inc stock worth over $195,390 and over the last 9 years he sold PTE stock worth over $374,757. In addition, he makes $649,256 as Pres & CEO at PolarityTE Inc.
Sign up
Mr Hague PTE stock SEC Form 4 insiders trading
Mr has made over 8 trades of the PolarityTE Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 10,208 units of PTE stock worth $8,473 on 9 August 2021.
The largest trade he's ever made was selling 12,950 units of PolarityTE Inc stock on 7 February 2020 worth over $39,109. On average, Mr trades about 1,303 units every 31 days since 2015. As of 9 August 2021 he still owns at least 814,123 units of PolarityTE Inc stock.
You can see the complete history of Mr Hague stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Richard Hague biography
Richard Hague is the Pres & CEO at PolarityTE Inc.
What is the salary of Mr Hague?
As the Pres & CEO of PolarityTE Inc, the total compensation of Mr Hague at PolarityTE Inc is $649,256. There are no executives at PolarityTE Inc getting paid more.
How old is Mr Hague?
Mr Hague is 61, he's been the Pres & CEO of PolarityTE Inc since . There are 1 older and 3 younger executives at PolarityTE Inc. The oldest executive at PolarityTE Inc is Dr. Stephen Milner M.D., DDS, DSc, FRCSE, FACS, 72, who is the Chief Clinical Officer & Member of Clinical Advisory Board.
What's Mr Hague's mailing address?
Richard's mailing address filed with the SEC is 32 Wiggins Ave, Bedford, MA 01730, USA.
Insiders trading at PolarityTE Inc
Over the last 6 years, insiders at PolarityTE Inc have traded over $998,958 worth of PolarityTE Inc stock and bought 381,180 units worth $1,230,731 . The most active insiders traders include Steve Gorlin, Peter A Cohen, ePaul Elliot Mann. On average, PolarityTE Inc executives and independent directors trade stock every 21 days with the average trade being worth of $3,753. The most recent stock trade was executed by Chris Nolet on 12 January 2023, trading 36,497 units of PTE stock currently worth $8,759.
What does PolarityTE Inc do?
polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™
What does PolarityTE Inc's logo look like?
Complete history of Mr Hague stock trades at Anika Therapeutics e PolarityTE Inc
PolarityTE Inc executives and stock owners
PolarityTE Inc executives and other stock owners filed with the SEC include:
-
Richard Hague,
Pres & CEO -
Cameron J. Hoyler,
Gen. Counsel, Sec. and Exec. VP of Corp. Devel. & Strategy -
Daniel Gasiorowski,
Investor Relations Contact Officer -
Wladyslaw Zmuda,
Member of the Supervisory Board -
Michal Zadlo,
Member of the Supervisory Board -
Beata Sobocinska,
Member of the Supervisory Board -
Kamila Krawiec,
Member of the Supervisory Board -
Michal Herominski,
Member of the Supervisory Board -
Patryk Gall,
Member of the Supervisory Board -
Emil Cybulski,
Member of the Supervisory Board -
Pawel Cieslik,
Member of the Supervisory Board -
Maria Biernacik-Bankowska,
Member of the Supervisory Board -
Agnieszka Kosno,
Chief Accounting Officer -
Zbigniew Stawinoga,
Chairman of the Management Board -
Rafal Markiewicz,
Chairman of the Supervisory Board -
Mark E. Lehman J.D.,
Chief Legal Officer -
Ryan Mathis M.D.,
Chief Medical Officer -
Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D.,
Sr. VP of Corp. Devel. & Pres of Contract Services -
Dr. Stephen Milner M.D., DDS, DSc, FRCSE, FACS,
Chief Clinical Officer & Member of Clinical Advisory Board -
Alain Adam,
VP of Sales -
Angela Ziegler,
VP of Marketing & PR -
Rich Haerle,
VP of Investor Relations & Strategy -
Nikolai Sopko,
Chief Scientific Officer and VP of R&D -
Jacob Alexander Patterson,
Chief Financial Officer -
Jacob Alexander Patterson,
Chief Financial Officer -
Chris Nolet,
Director -
Jessica Xiaolin Shen,
Director -
David B Seaburg,
Director -
Jon Mogford,
Director -
Rainer M Erdtmann,
Director -
Peter A Cohen,
Director -
Paul Elliot Mann,
Chief Financial Officer -
Edward Winslow Swanson,
Chief Trans. Med. Officer -
Steve Gorlin,
Director -
Jeffrey Hansen Dyer,
Director -
Willie C. Bogan,
Director -
Minnie Baylor Henry,
Director -
Denver Lough,
-
Richard Hague,
Chf. Exec. Off. & Pres. -
Cameron J. Hoyler,
Gen. Counsel & Exec. VP